Literature DB >> 22226481

Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.

Toon Van Gorp1, Joan Veldman, Ben Van Calster, Isabelle Cadron, Karin Leunen, Frederic Amant, Dirk Timmerman, Ignace Vergote.   

Abstract

PURPOSE: The combination of two tumour markers, CA125 and HE4, in the risk of ovarian malignancy assay (ROMA) has been shown to be successful in classifying patients into those who have a high or low risk of epithelial ovarian cancer. In the present study, the diagnostic accuracy of ROMA was assessed and compared to the diagnostic accuracy of the two most widely used ultrasound methods, namely the risk of malignancy index (RMI) and subjective assessment by ultrasound.
METHODS: From August, 2005 to March, 2009, 432 women with a pelvic mass who were scheduled to have surgery were enrolled in a single-centre prospective cohort study. A preoperative ultrasound was performed and preoperative CA125 and HE4 serum levels were measured. Once the final surgical pathology reports were obtained, the diagnostic accuracy and performance indices of ROMA, RMI and subjective assessment were calculated.
RESULTS: Of the 432 eligible patients, 374 could be analysed. Subjective assessment had the highest area under the receiver operator characteristic curve (AUC) (0.968, 95%CI:0.945-0.984), followed by the RMI (0.931, 95%CI:0.901-0.955). The subjective assessment and RMI both had significantly higher AUCs than the ROMA (0.893, 95%CI:0.857-0.922; P<0.0001 and P=0.0030, respectively). The pre- and postmenopausal populations generated similar results.
CONCLUSION: Although new tumour markers models are promising, they do not contribute significantly to the diagnosis of ovarian cancer. Ultrasound, especially subjective assessment by ultrasound, remains superior in discriminating malignant from benign ovarian masses.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22226481     DOI: 10.1016/j.ejca.2011.12.003

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  29 in total

1.  Ultrasound Features Improve Diagnostic Performance of Ovarian Cancer Predictors in Distinguishing Benign and Malignant Ovarian Tumors.

Authors:  Yong-Ning Chen; Fei Ma; Ya-di Zhang; Li Chen; Chan-Yuan Li; Shi-Peng Gong
Journal:  Curr Med Sci       Date:  2020-03-13

Review 2.  Diagnosis, treatment, and follow-up of borderline ovarian tumors.

Authors:  Daniela Fischerova; Michal Zikan; Pavel Dundr; David Cibula
Journal:  Oncologist       Date:  2012-09-28

3.  Falsely elevated human epididymis protein 4 results and Risk of Ovarian Malignancy Algorithm in polymorbid women after solid organ transplantation: A pilot and case-control study.

Authors:  Janka Franeková; Josef Cindr; Petra Lavríková; Jitka Komrsková; Peter Sečník; Věra Lánská; Antonín Jabor
Journal:  J Clin Lab Anal       Date:  2018-03-24       Impact factor: 2.352

Review 4.  The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.

Authors:  Archana R Simmons; Keith Baggerly; Robert C Bast
Journal:  Oncology (Williston Park)       Date:  2013-06       Impact factor: 2.990

5.  Multianalyte assay systems in the differential diagnosis of ovarian cancer.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Expert Opin Med Diagn       Date:  2012-03

Review 6.  Ultrasound in gynecological cancer: is it time for re-evaluation of its uses?

Authors:  Daniela Fischerova; David Cibula
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

7.  Fertility-Preserving Surgery of Borderline Serous Ovarian Tumors: A Case Report.

Authors:  Ipsita Mohapatra; Subha R Samantaray; Nikku Harshini
Journal:  Cureus       Date:  2022-04-13

Review 8.  Biomarker testing for ovarian cancer: clinical utility of multiplex assays.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Mol Diagn Ther       Date:  2013-06       Impact factor: 4.074

Review 9.  In 2014, can we do better than CA125 in the early detection of ovarian cancer?

Authors:  Joshua G Cohen; Matthew White; Ana Cruz; Robin Farias-Eisner
Journal:  World J Biol Chem       Date:  2014-08-26

10.  IOTA Simple Ultrasound Rules for Triage of Adnexal Mass: Experience from South India.

Authors:  Jyothi Shetty; Aruna Saradha; Deeksha Pandey; Rajeshwari Bhat; Sunanda Bharatnur
Journal:  J Obstet Gynaecol India       Date:  2019-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.